A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care (SOC) chemotherapy and chemoradiation to SOC chemotherapy and chemoradiation therapy alone in patients with borderline resectable or locally adv...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of surgery Vol. 275; no. 1; p. 45
Main Authors:	Hewitt, Daniel Brock, Nissen, Nicholas, Hatoum, Hassan, Musher, Benjamin, Seng, John, Coveler, Andrew L, Al-Rajabi, Raed, Yeo, Charles J, Leiby, Benjamin, Banks, Joshua, Balducci, Lodovico, Vaccaro, Gina, LoConte, Noelle, George, Thomas J, Brenner, Warren, Elquza, Emad, Vahanian, Nicholas, Rossi, Gabriela, Kennedy, Eugene, Link, Charles, Lavu, Harish
Format:	Journal Article
Language:	English
Published:	United States 01.01.2022
Subjects:	Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Vaccines - adverse effects Cancer Vaccines - therapeutic use Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Fluorouracil - adverse effects Fluorouracil - therapeutic use Humans Immunotherapy - adverse effects Irinotecan - adverse effects Irinotecan - therapeutic use Leucovorin - adverse effects Leucovorin - therapeutic use Male Middle Aged Neoadjuvant Therapy - adverse effects Oxaliplatin - adverse effects Oxaliplatin - therapeutic use Paclitaxel - adverse effects Paclitaxel - therapeutic use Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - surgery Pancreatic Neoplasms - therapy Progression-Free Survival Standard of Care Survival Analysis
ISSN:	1528-1140, 1528-1140
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!